Sanofi | SNY
Stock Price
52.63
Daily Change
0.65 1.24%
Monthly
8.98%
Yearly
5.48%
Q1 Forecast
51.11



Peers Price Chg Day Year Date
AbbVie 170.62 0.22 0.13% 3.32% Jan/24
Amgen 276.56 -1.22 -0.44% -9.47% Jan/24
AstraZeneca 11,064.00 18.00 0.16% 5.90% Jan/24
Bristol-Myers Squibb 59.80 0.67 1.13% 20.54% Jan/24
Corcept Therapeutics 60.69 -1.61 -2.58% 165.35% Jan/24
Genmab 1,503.00 -9.00 -0.60% -21.94% Jan/24
Galapagos 22.70 -0.08 -0.35% -34.54% Jan/24
GlaxoSmithKline 1,356.50 -7.00 -0.51% -10.83% Jan/24
Glaxosmithkline 34.29 0.24 0.70% -11.72% Jan/24
Indivior 953.00 -6.00 -0.63% -32.07% Jan/24
J&J 146.62 0.07 0.05% -7.76% Jan/24
Eli Lilly 784.04 17.84 2.33% 24.92% Jan/24
Merck 96.03 -0.53 -0.55% -19.22% Jan/24
Novartis 90.26 0 0% -2.68% Jan/24
Novartis 99.93 -0.08 -0.08% -7.09% Jan/24
Prestige Brands 76.75 0.02 0.03% 24.86% Jan/24
Pacira 24.70 1.37 5.87% -23.74% Jan/24
Pfizer 26.04 -0.43 -1.62% -8.08% Jan/24
Perrigo 24.82 0.11 0.42% -24.83% Jan/24
Drreddys Laboratories 14.01 -0.14 -0.99% -80.08% Jan/24
Roche Holding 274.90 0.50 0.18% 13.60% Jan/24
Sanofi 52.63 0.65 1.24% 5.48% Jan/24
Supernus Pharmaceuticals 39.08 0.44 1.14% 35.46% Jan/24
UCB 188.05 4.25 2.31% 119.68% Jan/24
Canopy Growth 3.18 0.02 0.63% -49.28% Jan/24
Zoetis 168.54 1.53 0.92% -10.03% Jan/24

Sanofi traded at $52.63 this Friday January 24th, increasing $0.65 or 1.24 percent since the previous trading session. Looking back, over the last four weeks, Sanofi gained 8.98 percent. Over the last 12 months, its price rose by 5.48 percent. Looking ahead, we forecast Sanofi to be priced at 51.11 by the end of this quarter and at 49.88 in one year, according to Trading Economics global macro models projections and analysts expectations.

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.